US 6,274,722 B1Granted

Expression of a foamy virus envelope protein

AssigneeTransgene S.A.

InventorsDirk Lindemann, Axel Rethwilm

Life of this patent

Estimating the term…

Abstract

The invention concerns constructs for the expression of a protein comprising at least a modified FV envelope protein, the protein so obtained as well as the complementation cell line permitting the production of pseudotyped viral particle. It also concerns pharmaceutical composition comprising said particles and a method for treating a disease.

Claims3

Dependent claims

A protein expressed by a vector, wherein said protein comprises a functional modified foamy virus (FV) envelope protein, wherein said functional modified FV envelope protein is truncated at residue 981.

Dependencies are inferred from the claim text.

Facts

Application: 09/617,917Filed 17 Jul 2000 · division
Priority: 14 Mar 1997
Granted: 14 Aug 2001
Term ends: Not estimatedThe source records don’t support an estimate.

Classification14 codes

C07K 14/005
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof: from viruses
C12N 15/86
For animal cells: viral vectors
C07K 2319/00
Fusion polypeptide
C12N 2740/13043
Use of virus, viral particle or viral elements as a vector: viral genome or elements thereof as genetic vector

Family

Application08/816,439Parent of this division · filed 14 Mar 1997
Application09/305,086Parent of this division · filed 4 May 1999
US 5,929,222 AParent of this division
US 6,150,138 ARelated patent
US 6,274,722 B1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results